In a filing, Artivion Inc revealed its SVP, Clinical & MD Affair Stanton Marshall S. unloaded Company’s shares for reported $0.44 million on Jun 17 ’25. In the deal valued at $29.50 per share,15,000 shares were sold. As a result of this transaction, Stanton Marshall S. now holds 64,200 shares worth roughly $2.0 million.
Then, MARSHALL STANTON bought 15,000 shares, generating $442,500 in total proceeds.
Before that, Stanton Marshall S. sold 26,132 shares. Artivion Inc shares valued at $743,131 were divested by the SVP, Clinical & MD Affair at a price of $28.44 per share. As a result of the transaction, Stanton Marshall S. now holds 79,200 shares, worth roughly $2.46 million.
Canaccord Genuity initiated its Artivion Inc [AORT] rating to a Buy in a research note published on June 17, 2025; the price target was $35. A number of analysts have revised their coverage, including JMP Securities’s analysts, who began to cover the stock in late October with a ‘”a Mkt outperform”‘ rating. Lake Street also remained covering AORT and reiterated its “Buy” recommendation on September 27, 2022. Lake Street started covering the stock on August 08, 2022. It rated AORT as “a Buy”.
Price Performance Review of AORT
On Monday, Artivion Inc [NYSE:AORT] saw its stock fall -0.29% to $31.1. Over the last five days, the stock has gained 0.81%. Artivion Inc shares have risen nearly 27.72% since the year began. Nevertheless, the stocks have risen 8.78% over the past one year. While a 52-week high of $32.33 was reached on 01/16/25, a 52-week low of $21.97 was recorded on 04/09/25.
Levels Of Support And Resistance For AORT Stock
The 24-hour chart illustrates a support level at 30.89, which if violated will result in even more drops to 30.68. On the upside, there is a resistance level at 31.49. A further resistance level may holdings at 31.87.
How much short interest is there in Artivion Inc?
A steep rise in short interest was recorded in Artivion Inc stocks on 2025-06-13, dropping by -2.81 million shares to a total of 1.52 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 4.34 million shares. There was a decline of -184.65%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 03, 2022 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $30 price target.
